Expensive Oral Agents Responsible for Cost Shifting in Cancer
The American Journal of Managed Care
April 29, 2016
Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.
Read Full Article Here